In the future, this non-invasive imaging strategy may be used to evaluate ICOS agonist monotherapy or in combination with other immunotherapy and to assess the changes in CD8+ T-cell infiltration in tumor throughout the treatment regime. Here, CD8A is linked to neoplasm.